Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disaggregating Gender Inequality Globally: Health Systems, Gender Inequality, and Female Pan-Cancer Outcomes.

JCO global oncology·2026
Same author

Development of a rapid ex vivo tumor platform for drug response prediction in lung cancer.

NPJ precision oncology·2026
Same author

Comment on the STARLET Study.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Letter to the Editor regarding "Questionable indication for postoperative radiotherapy after surgery for metastases of the major long bones": A cautionary note on methodology and analysis.

Journal of bone oncology·2026
Same author

Political determinants of melanoma: Global inequities in skin cancer care.

JAAD international·2026
Same author

Transformer-based cardiac substructure segmentation from contrast and non-contrast computed tomography for radiotherapy planning.

Physics and imaging in radiation oncology·2026

Related Experiment Video

Updated: Sep 8, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

Current Controversies and Challenges in Non-Oncogene-Addicted Synchronous Oligometastatic Non-Small Cell Lung Cancer:

Mandy Jongbloed1, Martina Bortolot2, Jonas Willmann3,4

  • 1Department of Pulmonary Diseases, GROW - Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands.

JAMA Oncology
|September 4, 2025
PubMed
Summary

Local radical treatment (LRT) did not improve survival for patients with synchronous oligometastatic non-small cell lung cancer (NSCLC) receiving maintenance immunotherapy. The existence of a true oligometastatic state remains uncertain.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K

Related Experiment Videos

Last Updated: Sep 8, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K

Area of Science:

  • Oncology
  • Medical Imaging
  • Genomics

Background:

  • Advancements in imaging and therapies suggest potential benefits of curative-intent treatment for synchronous oligometastatic disease (sOMD).
  • The NRG-LU002 trial investigated the addition of local radical treatment (LRT) to maintenance systemic therapy in oligometastatic non-small cell lung cancer (NSCLC).

Purpose of the Study:

  • To discuss challenges and controversies in treating non-oncogene-addicted sOMD.
  • To evaluate the role of LRT in contemporary immunotherapy regimens and explore the existence of a true sOMD state.

Main Methods:

  • Review of current literature and clinical trial data, including the NRG-LU002 trial.
  • Discussion of biological factors influencing metastatic potential and imaging limitations in distinguishing sOMD from widespread disease.

Main Results:

  • The NRG-LU002 trial found no significant improvement in progression-free or overall survival with LRT added to maintenance systemic therapy for oligometastatic NSCLC.
  • Current imaging modalities cannot reliably distinguish true sOMD from early-stage widespread metastatic disease, complicating patient selection for radical strategies.

Conclusions:

  • The existence of synchronous oligometastatic NSCLC as a distinct biological entity is debated.
  • Biomarkers like ctDNA, microRNA, and radiomics require further validation for improved patient selection in clinical trials, emphasizing the need for translational research.